Microvascular Angina and INOCA

INOCA describes myocardial ischaemia occurring without a flow-limiting obstruction in the large coronary arteries. Coronary microvascular dysfunction and coronary spasm are important causes. Symptoms are real and may affect quality of life and cardiovascular risk even when angiography does not show a severe stenosis.

Diagnosis

Assessment first excludes acute coronary syndrome and important obstructive disease. Stress imaging may demonstrate ischaemia. In selected patients, invasive coronary-function testing can measure coronary flow reserve and microvascular resistance and assess for vasospasm. The result helps identify the mechanism rather than treating every patient identically.

Treatment

Risk-factor control is essential. Antianginal treatment is matched to the endotype, heart rate, blood pressure and coexisting disease. Medicines useful for microvascular dysfunction may differ from those preferred for vasospastic disease. Regular review considers symptom burden, functional capacity and medicine tolerance.

New or severe chest pain at rest, sweating, fainting or marked breathlessness requires emergency assessment.

Clinical Depth and Risk Assessment

Risk is not defined by the diagnostic label alone. Symptoms, ECG and rhythm findings, ventricular function, myocardial scar or structural change, family history, associated disease and previous events are integrated. Genetic results, when relevant, require expert interpretation; a variant of uncertain significance is not equivalent to a diagnosis.

Diagnostic Strategy and Limitations

Testing is selected to answer a specific question. ECG, ambulatory monitoring, echocardiography, cardiac MRI, CT, laboratory testing, exercise assessment or invasive evaluation have complementary roles. A normal test may not exclude an intermittent disorder, while an abnormal measurement must be checked against technical quality and clinical probability.

Treatment Decision Framework

Treatment may combine risk-factor control, condition-specific medicines, rhythm or heart-failure therapy, catheter procedures, surgery and implanted devices. These options address different mechanisms and are not automatically substitutes for one another. Expected benefit, uncertainty, procedural burden and the patient’s informed preferences should be discussed explicitly.

Long-Term Follow-up

Follow-up assesses symptoms, exercise capacity, rhythm burden, ventricular function and treatment tolerance over time. Family screening may be appropriate in inherited or suspected inherited disease. New fainting, sustained rapid rhythm, chest pain, neurological symptoms or rapidly worsening breathlessness requires urgent assessment.

Questions to Discuss With the Cardiology Team

• Which finding has the greatest influence on my present risk?
• Which test or treatment would genuinely change management?
• What symptoms should lead to an earlier appointment or emergency care?
• Do relatives need clinical or genetic assessment?

Medical Information Note

This page supports an informed discussion with the clinical team. It does not provide a personal diagnosis, medicine dose or sports-clearance decision.